| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9682968 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(10 years from now) | |
| US11603363 | NOVARTIS | Crystalline form of LNP023 |
May, 2041
(17 years from now) | |
Fabhalta is owned by Novartis.
Fabhalta contains Iptacopan Hydrochloride.
Fabhalta has a total of 2 drug patents out of which 0 drug patents have expired.
Fabhalta was authorised for market use on 05 December, 2023.
Fabhalta is available in capsule;oral dosage forms.
Drug patent challenges can be filed against Fabhalta from 06 December, 2027.
The generics of Fabhalta are possible to be released after 25 May, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
More Information on Dosage
FABHALTA family patents
